Sezen ATASOY, Nur ÖZTEN KANDAŞ, Beyza GÖNCÜ, Sevde HASANOĞLU, Yunus KAYALI, Emrah YÜCESAN

Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis

Background/aim: MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition, obtaining miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant differences in miRNA profiles between patients and healthy controls. Materials and methods: Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients, thirty healthy individuals were screened for miRNA profile, and candidate miRNAs were validated. Whole urinary and serum miRNA profile was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcriptionpolymerase chain reaction. Results: When we analyzed the urinary samples of PC patients, 49 miRNAs were detected to be upregulated and 14 miRNAs were found to be downregulated when compared with healthy controls. According to the serum samples, 19 miRNAs were found to be upregulated, and 21 miRNAs were found to be downregulated when compared with healthy individuals as well. Interestingly, we detected only four overlapping miRNAs (MIR320A, MIR4535, MIR4706, MIR6750) that commonly increase or decrease in both serum and urine samples. Among them, MIR320A was found to be downregulated, and MIR4535, MIR4706, and MIR6750 were found to be upregulated for urine samples. However, only MIR6750 was upregulated and the other three miRNAs were downregulated for serum samples. Conclusion: Notably, the expression profile of MIR320A was significantly altered in urine specimens of prostate cancer patients. We considered that MIR320A has been evaluated as a valuable biomarker that can be used in the early diagnosis of PC.Key words: Prostate cancer, biomarker, microarray, miRNA profiling

PDF

___

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013; 63 (1): 11-30. doi: 10.3322/ caac.21166
2. Bashir MN. Epidemiology of Prostate Cancer. The Asian Pacific Journal of Cancer Prevention 2015; 16 (13): 5137-5141. doi: 10.7314/APJCP.2015.16.13.5137
3. Akbayir S, Muslu N, Erden S, Bozlu M. Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. Turkish Journal of Urology 2016; 42 (4) : 247-255. doi: 10.5152/tud.2016.52463
4. Deng J, Tang J, Wang G, Zhu YS. Long non-coding RNA as potential biomarker for prostate cancer: is it making a difference? International Journal of Environmental Research and Public Health 2017; 14 (3). doi: 10.3390/ijerph14030270
5. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews Cancer 2008; 8 (4): 268-278. doi: 10.1038/nrc2351
6. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C et al. Micrornas in prostate cancer: an overview. Oncotarget 2017; 8 (30): 50240-50251. doi: 10.18632/oncotarget.16933
7. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Letters 2007; 249 (1): 30-39. doi: 10.1016/j. canlet.2006.12.022
8. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. European Urology 2008; 53 (3): 468-477. doi: 10.1016/j.eururo.2007.10.047
9. Kim EH, Andriole GL. Prostate-specific antigen-based screening: controversy and guidelines. BMC Medicine 2015; 24 (13): 61. doi: 10.1186/s12916-015-0296-5
10. Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World Journal of Biological Chemistry 2017; 8 (1): 45-56. doi: 10.4331/wjbc. v8.i1.45
11. Celano M, Rosignolo F, Maggisano V, Pecce V, Iannone M et al. MicroRNAs as biomarkers in thyroid carcinoma. International Journal of Genomics 2017; 2017: 6496570. doi: 10.1155/2017/6496570
12. Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H et al. MicroRNAs as biomarkers in colorectal cancer. Cancers (Basel) 2017; 9 (9): 124. doi: 10.3390/cancers9090124
13. Detassis S, Grasso M, Del Vescovo V, Denti MA. microRNAs Make the call in cancer personalized medicine. Frontiers in Cell and Developmental Biology 2017; 5: 86. doi: 10.3389/ fcell.2017.00086
14. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM et al. Biological functions of microRNAs: a review. Journal of Physiology and Biochemistry 2011; 67 (1): 129-139. doi: 10.1007/s13105-010-0050-6
15. Spakova I, Zelko A, Rabajdova M, Kolarcik P, Rosenberger J et al. MicroRNA molecules as predictive biomarkers of adaptive responses to strength training and physical inactivity in haemodialysis patients. Scientific Reports 2020; 10 (1): 15597. doi: 10.1038/s41598-020-72542-1
16. Yang Y, Ma L, Qiao X, Zhang X, Dong SF et al. Salivary microRNAs show potential as biomarkers for early diagnosis of malignant pleural effusion. Translational Lung Cancer Research 2020; 9 (4): 1247-1257. doi: 10.21037/tlcr-19-530
17. Zhai C, Li R, Hou K, Chen J, Alzogool M et al. Value of blood-based microRNAs in the diagnosis of acute myocardial infarction: a systematic review and meta-analysis. Frontiers in Physiology 2020; 11: 691. doi: 10.3389/fphys.2020.00691
18. Zuo Z, Jiang Y, Zeng S, Li Y, Fan J et al. The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: A meta-analysis. Pathology - Research and Practice 2020; 216 (10): 153130. doi: 10.1016/j.prp.2020.153130
19. Wu D, Ni J, Beretov J, Cozzi P, Willcox M et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Critical Reviews in Oncology/Hematology 2017; 118: 15-26. doi: 10.1016/j.critrevonc.2017.08.002
20. Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ et al. The potential of microRNAs as human prostate cancer biomarkers: a metaanalysis of related studies. Journal of Cellular Biochemistry 2018; 119 (3): 2763-2786. doi: 10.1002/jcb.26445
21. Wang K. The ubiquitous existence of MicroRNA in body fluids. Clinical Chemistry 2017; 63 (3): 784-785. doi: 10.1373/ clinchem.2016.267625
22. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL et al. Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer 2012; 106 (4): 768- 774. doi: 10.1038/bjc.2011.595
23. Mestdagh P, van Vlierberghe P, de Weer A, Muth D, Westermann F et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology 2009; 10 (6): 64. doi: 10.1186/gb-2009-10-6-r64
24. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research 2014; 42(Database issue): 68-73. doi: 10.1093/ nar/gkt1181
25. Ma S, Chan YP, Kwan PS, Lee TK, Yan M et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Research 2011; 71 (2): 583-592. doi: 10.1158/0008-5472.can-10-2587
26. Massillo C, Dalton GN, Farre PL, De Luca P, De Siervi A. Implications of microRNA dysregulation in the development of prostate cancer. Reproduction 2017; 154 (4): 81-97. doi: 10.1530/REP-17-0322
27. Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S et al. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. International Journal of Cancer 2015; 136 (4): 875-879. doi: 10.1002/ijc.29054
28. Reza AM, Choi YJ, Yasuda H, Kim JH. Human adipose mesenchymal stem cell-derived exosomal-miRNAs are critical factors for inducing anti-proliferation signalling to A2780 and SKOV-3 ovarian cancer cells. Scientific Reports 2016; 6: 38498. doi: 10.1038/srep38498
29. Jima D.D, Zhang J, Jacobs C, Richards KL, Dunphy CH et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010; 116 (23): e118-27. doi: 10.1182/ blood-2010-05-285403
30. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Research 2011; 71 (1): 78-86. doi: 10.1158/0008-5472. can-10-1869
31. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL et al. MicroRNA expression profiling in prostate cancer. Cancer Research 2007; 67 (13): 6130-6135. doi: 10.1158/0008- 5472.can-07-0533
32. Ristau J, Staffa J, Schrotz-King P, Gigic B, Makar KW et al. Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention 2014; 23 (12): 2632-2637. doi: 10.1158/1055- 9965.epi-14-0556
33. Okato A, Goto Y, Kurozumi A, Kato M, Kojima S et al. Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer. International Journal of Oncology 2016; 49 (1): 111-122. doi: 10.3892/ijo.2016.3522
34. Zhao S, Wang Y, Lou Y, Wang Y, Sun J et al. MicroRNA320a suppresses tumour cell proliferation and invasion of renal cancer cells by targeting FoxM1. Oncology Reports 2018; 40 (4): 1917-1926. doi: 10.3892/or.2018.6597
35. Ladewig E, Okamura K, Flynt AS, Westholm JO, Lai EC. Discovery of hundreds of mirtrons in mouse and human small RNA data. Genome Research 2012; 22 (9): 1634-1645. doi: 10.1101/gr.133553.111
36. Ma W, Kang Y, Ning L, Tan J, Wang H et al. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Experimental and Therapeutic Medicine 2017; 14 (4): 2853-2862. doi: 10.3892/etm.2017.4847